Lobectomy versus sublobar resection for stage I non-small cell lung cancer: an umbrella review of evidence quality, overlap, surgical-extent heterogeneity, and survival outcomes - Top-Institutions - MDSpire

Lobectomy versus sublobar resection for stage I non-small cell lung cancer: an umbrella review of evidence quality, overlap, surgical-extent heterogeneity, and survival outcomes

  • By

  • Xiang Lin

  • Jingwen Zhang

  • Beinuo Wang

  • Zhenghao Dong

  • Yu Tong

  • Jian Zhou

  • Hu Liao

  • June 5, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Thoracic Surgery
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Thoracic Surgery
    • Oncology

  • #3

    Roswell Park Comprehensive Cancer Center
    Roswell Park Comprehensive Cancer Center

    Buffalo, New York

    Key Differentiators

    • Thoracic Surgery
    • Oncology

  • #4

    Poznan University of Medical Sciences
    Poznan University of Medical Sciences

    Poznan, Poland

    Key Differentiators

    • Thoracic Surgery

  • #5

    Rush University Medical Center
    Rush University Medical Center

    Chicago, Illinois

    Key Differentiators

    • Thoracic Surgery

Original Source(s)

Lobectomy versus sublobar resection for stage I non-small cell lung cancer: an umbrella review of evidence quality, overlap, surgical-extent heterogeneity, and survival outcomes

  • by Xiang Lin, Jingwen Zhang, Beinuo Wang, Zhenghao Dong, Yu Tong, Jian Zhou, Hu Liao

  • June 5, 2026

Related Content

Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax

A case report of splenic malignancy originating from the liver

Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial